home > products & services > the simcyp simulator
The Simcyp Simulator
The Simcyp Population-based ADME Simulator is the pharmaceutical industry's most sophisticated platform for the prediction of drug-drug interactions and pharmacokinetic outcomes in clinical populations.
It contains numerous databases containing human physiological, genetic and epidemiological information. By integrating this information with your in vitro data, the Simulator allows you to predict pharmacokinetic behaviour in ‘real-world’ populations. This automated prediction of in vivo outcomes accelerates the assessment of large numbers of compounds, saving time and cost.
The Simcyp Population Based ADME Simulator provides valuable information for key management decisions relating to clinical trial design, clinical trial avoidance, and drug-drug interaction (DDI) information for the Summary of Product Characteristics (SPCs) and Prescribing Information sheets.
The Simcyp Simulator can also identify key pre-clinical data requirements, which can prove extremely valuable for redefining and optimising early drug development processes and procedures.
Key features of the Simulator:
- Fast
- User-friendly
- Up-to-date
- Transparent methods
- Cost-saving
- Time-saving
|
Key features |
Key benefits |
- Automated in vitro extrapolation to predict in vivo outcomes, supporting the assessment of large numbers of compounds metabolised by multiple enzymes
|
- Facilitates drug development by optimising the nomination of candidate drugs and the selection and design of in vivo studies, saving time and money
|
- Incorporates inter-subject physiological variability
|
- Allows prediction of drug disposition in real-world populations
|
- High speed, user friendly desk-top application
|
- Rapid identification of the mix of characteristics of individuals at greatest risk
|
- Batch processing facility
|
- Automates multiple simulations so a large number can be run in succession without further user input. This has proved particularly useful for sensitivity analysis.
|
- Transparent algorithms and methodology and easily understood visual outputs through a variety of graphics interfaces
|
- User-friendly and informative
|
- Incorporates leading-edge science with continually updated databases
|
- Your outputs are up-to-date, based on the latest scientific data
|
- Consortium members guide the development of the Simulator and share 'best practice'
|
- Simulator meets the current and future needs of the global pharmaceutical industry
|
- Supported by scientific and technical teams
|
- Help and advice at the end of the telephone
|
| |
|
Simcyp Population-based ADME Simulator, Version 9.2
New features have been incorporated into the platform in 2009 and changes have been made to enhance the capability and improve performance of the Simulator. These modifications were determined in consultation with the Simcyp Consortium and include:
- Expansion of PBPK models to include transporter-mediated efflux & influx to different organs/tissues
- Further developments to the Advanced Dissolution, Absorption and Metabolism (ADAM) model to incorporate the automated calculation of bile effects on solubility and dissolution, an enterohepatic recirculation model with links to transporter effects and pH effects on permeability
- Expansion of non-parenteral absorption models for simulation of dermal and pulmonary routes of administration
- Implementation of an automated sensitivity tool for analysing changes in output parameters as a function of the user-defined input variables
- Implementation of custom trial design grids to provide greater flexibility when designing virtual clinical trials
- Development of a module for population fitting of PBPK models with clinical data. This facilitates covariate recognition and parameter estimation through incorporation of prior knowledge of systems biology and drug specific data
In addition to implementation of the 2007 wish list, the Simcyp team has also made some significant changes to further improve the functionality and simulation speed of the Simulator. This includes restructuring the databases to handle increasing datasets. For ease-of-use, the trial design fields have been updated and an automated compound import tool has been added which facilitates data handling from Excel. Compound files within the Simulator have been updated to reflect the recent advances which have been reported in the literature.
The Simcyp Paediatric module has also been updated and now incorporates many of the functionalities of Simcyp’s flagship simulator. Modifications have been made which enhance clearance prediction capabilities through expansion of the data entry options to ensure that maturation and age-related functions are incorporated for all metabolic routes.
Simcyp Paediatric 2009 enables drug-drug interactions (DDI), involving up to four compounds, to be investigated. Different interaction mechanisms including competitive inhibition, mechanism-based inhibition and induction of various drug metabolising pathways are accommodated. Variability within paediatric sub-populations can also be simulated which allows extreme cases to be identified.
Simcyp Rat 2009, a whole-body PBPK model, is now also available to Consortium members to access as an additional Simcyp module.